Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02916745 · ClinicalTrials.gov registry record · Phase 1

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis, sponsored by Concordia Laboratories.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
7
Study locations

NCT02916745: Completed Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis, sponsored by Concordia Laboratories.

NCT02916745 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis that has completed, run by Concordia Laboratories. The registered enrollment target is 5 participants, below the 285-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02916745, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis, has completed, sponsored by Concordia Laboratories.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
7
Study locations

Study Summary

This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Canada. Participation will last 6 months.

Primary Outcome

Number of times photodynamic therapy was delivered into the tumor using navigational bronchoscopy for each subject.

Interventions

  • DRUG Porfimer sodium
  • DEVICE Fiber optic

Study Locations (7)

Florida

  • University of Florida - Gainesville

Georgia

  • Southeastern Regional Medical Center - Atlanta

Illinois

  • Alexian Brothers Hospital Network - Elk Grove Village

Oklahoma

  • Southwestern Regional Medical Center - Tulsa

Washington

  • Providence Medical Research Center - Spokane

Wisconsin

  • University of Wisconsin-Madison - Madison

Ontario

  • Toronto General Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2017-01-26
Est. Completion 2019-04-12
Phase Phase 1
Concordia Laboratories

4 total trials

What the finished NCT02916745 record still lists

NCT02916745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 285-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Porfimer sodium is the first listed.

NCT02916745 lists 7 locations in 7 states (Florida, Georgia, Illinois).

Frequently Asked Questions

What is clinical trial NCT02916745 about?

NCT02916745 is a clinical study titled "Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer". This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Cana...

What is the current status of trial NCT02916745?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-01-26. Estimated completion is 2019-04-12.

What conditions does trial NCT02916745 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Lung Metastasis.

What interventions are being tested in trial NCT02916745?

The interventions under investigation include: Porfimer sodium (DRUG), Fiber optic (DEVICE).

Who is sponsoring clinical trial NCT02916745?

This trial is sponsored by Concordia Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02916745 being conducted?

This trial has 7 study locations across Florida, Georgia, Illinois, Oklahoma, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02916745's enrollment target sits among peer trials

5 60th of 59 the lowest of 59 other Non-small Cell Lung Cancer (NSCLC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02916745, the US trial registry maintained by the National Library of Medicine. NCT02916745 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.